MedTrace Logo

Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori

NCT02352701 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2015-08-27

No results posted yet for this study

Summary

This study compared efficacy and safety of basic triple therapy including Ilaprazole 10mg, Levofloxacin 500mg and Amoxicillin 1000mg BID for 10 days on the first line eradication treatment of H.pylori

Conditions

  • Helicobacter Infections

Interventions

DRUG

Noltec tab. 10mg

Ilaprazole 10mg BID dosage form : delayed release tablet

DRUG

Chongkundang Amoxicillin Cap. 500mg

Amoxicillin 1000mg, BID dosage form : capsule

DRUG

Cravit Tab. 500mg

Levofloxacin 500mg, BID dosage form : film coated tablet

Sponsors & Collaborators

  • Il-Yang Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Dongsoo Lee, MD, PhD. · The Catholic Univ. of Korea, Daejeon St.Mary Hospital

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02352701 on ClinicalTrials.gov